result 519 件
| Author | Yasuda, Yukiko| Sakai, Akiko| Ito, Sachio| Sasai, Kaori| Yamamoto, Hiromasa| Matsubara, Nagahide| Ouchida, Mamoru| Katayama, Hiroshi| Shimizu, Kenji| |
|---|---|
| Published Date | 2017-02 |
| Publication Title | Acta Medica Okayama |
| Volume | volume71 |
| Issue | issue1 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/54826 |
| JaLCDOI | 10.18926/AMO/54816 |
|---|---|
| FullText URL | 70_6_507.pdf |
| Author | Torigoe, Hidejiro| Toyooka, Shinichi| Yamamoto, Hiromasa| Soh, Junichi| Miyoshi, Shinichiro| |
| Abstract | We present the case of a 65-year-old Japanese man diagnosed with chronic empyema (without a bronchopleural fistula) that occurred 7 months after he underwent an extrapleural pneumonectomy for right malignant pleural mesothelioma (MPM). Following thoracic drainage and irrigation for 1 month, we performed surgery by a thoracoscopic approach, in light of his general condition. We performed debridement and removal of the Gore-Tex polytetrafluoroethylene (PTFE) patch that had been used for the reconstruction of the diaphragm and the pericardium. The empyema had not relapsed when he died from recurrence of the MPM at 4 months after the thoracoscopic surgery. This patientʼs case suggests that thoracoscopic debridement and patch removal can be a therapeutic option for not only early-stage (exudative or fibrinopurulent) empyema but also late-stage (organized and chronic) empyema without a bronchopleural fistula, particularly for patients in poor general condition. |
| Keywords | empyema chronic extrapleural pneumonectomy thoracoscopic debridement patch removal |
| Amo Type | Case Report |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-12 |
| Volume | volume70 |
| Issue | issue6 |
| Publisher | Okayama University Medical School |
| Start Page | 507 |
| End Page | 510 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 28003678 |
| Author | Ono, Miho| |
|---|---|
| Published Date | 2016-09-30 |
| Content Type | Thesis or Dissertation |
| Author | Taniguchi, Kohei| |
|---|---|
| Published Date | 2016-09-30 |
| Content Type | Thesis or Dissertation |
| Author | Saiga, Miho| |
|---|---|
| Published Date | 2016-09-30 |
| Content Type | Thesis or Dissertation |
| Author | Morita, Mizuki| Toyooka, Shinichi| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Article |
| Author | Kobashi, Kenta| Ishii, Hiroshi| Nishiyama, Kanako| Matsumi, Yuki| Hatano, Masahide| Fujiwara, Masamitsu| Kurokawa, Tatsuo| Tsunemitsu, Kensuke| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Shigeyasu, Kunitoshi| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/54607 |
|---|---|
| FullText URL | 70_5_425.pdf |
| Author | Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. |
| Keywords | breast cancer phase I trial docetaxel |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 425 |
| End Page | 427 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777441 |
| Web of Science KeyUT | 000388098700018 |
| JaLCDOI | 10.18926/AMO/54514 |
|---|---|
| FullText URL | 70_4_327.pdf |
| Author | Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi| |
| Abstract | A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8＋ T cells, which produce multiple cytokines. |
| Keywords | metformin CD8＋ T cells cancer immunology |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-08 |
| Volume | volume70 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 327 |
| End Page | 330 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27549683 |
| Web of Science KeyUT | 000384748600018 |
| FullText URL | K0005291_abstract_review.pdf K0005291_fulltext.pdf K0005291_summary.pdf |
|---|---|
| Author | Ito, Maiko| |
| Published Date | 2016-03-25 |
| Content Type | Thesis or Dissertation |
| Grant Number | 甲第5291号 |
| Granted Date | 2016-03-25 |
| Thesis Type | Doctor of Philosophy in Medical Science |
| Grantor | 岡山大学 |
| language | English |
| FullText URL | K0005250_abstract_review.pdf K0005250_fulltext.pdf |
|---|---|
| Author | Sugiu, Kumi| |
| Published Date | 2015-12-31 |
| Content Type | Thesis or Dissertation |
| Grant Number | 甲第5250号 |
| Granted Date | 2015-12-31 |
| Thesis Type | Doctor of Philosophy in Medical Science |
| Grantor | 岡山大学 |
| language | English |
| JaLCDOI | 10.18926/AMO/54003 |
|---|---|
| FullText URL | 70_1_45.pdf |
| Author | Maruyama, Hidehiko| Nakata, Yusei| Kanazawa, Akane| Kikkawa, Kiyoshi| |
| Abstract | Mothers of preterm infants may find it difficult to express breast milk. There is a low breast milk rate among preterm infants at discharge at our hospital, and here we tested the hypothesis that milk expression factors were the cause of the low rate. The study subjects were born before 33 gestational weeks at our hospital between March 2005 and June 2014. Nutritional evaluation was performed at discharge and noted whether breast milk, infant formula, or a mix of the 2 was being given. We compared the group given breast milk or the mix versus the group given formula. Of the 337 infants, 40 cases were excluded. Data from 297 infants were analyzed. The mean (SD) gestational age and birth weight were 29.5 (2.4) weeks and 1,230 (391) g, respectively. At discharge, 26 (8.8%), 102 (33.3%), and 174 (57.9%) infants were given breast milk, formula, and the mix, respectively. A multivariate logistic regression analysis showed that the first milk expression (h) was the risk factor for the formula group: adjusted odds ratio (95% confidence interval) 1.06 (1.02-1.09) and p=0.002. Delayed first milk expression could affect the low breast milk rate at discharge. Improvement of milk expression should be achieved to promote breastfeeding. |
| Keywords | breast milk breastfeeding formula milk expression preterm |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-02 |
| Volume | volume70 |
| Issue | issue1 |
| Publisher | Okayama University Medical School |
| Start Page | 45 |
| End Page | 49 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26899609 |
| Web of Science KeyUT | 000371288700006 |
| Author | Yoshimura, Teizo| Howard, O. M. Zack| Ito, Toshihiro| Kuwabara, Masaki| Matsukawa, Akihiro| Chen, Keqiang| Liu, Ying| Liu, Mingyong| Oppenheim, Joost J.| Wang, Ji Ming| |
|---|---|
| Published Date | 2013-03-18 |
| Publication Title | PLOS ONE |
| Volume | volume8 |
| Issue | issue3 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/53907 |
|---|---|
| FullText URL | 69_6_333.pdf |
| Author | Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro| |
| Abstract | We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients. |
| Keywords | breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2015-12 |
| Volume | volume69 |
| Issue | issue6 |
| Publisher | Okayama University Medical School |
| Start Page | 333 |
| End Page | 338 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26690243 |
| Web of Science KeyUT | 000368434500002 |
| FullText URL | K0005216_abstract_review.pdf K0005216_fulltext.pdf K0005216_fulltext_other.pdf |
|---|---|
| Author | Shimoyama, Kyoko| |
| Published Date | 2015-09-30 |
| Content Type | Thesis or Dissertation |
| Grant Number | 甲第5216号 |
| Granted Date | 2015-09-30 |
| Thesis Type | Doctor of Philosophy in Medical Science |
| Grantor | 岡山大学 |
| language | English |
| Title Alternative | Basic and clinical research regarding vascular endothelial function |
|---|---|
| FullText URL | 127_187.pdf |
| Author | Tsukahara, Hirokazu| |
| Keywords | アルギニン代謝 一酸化窒素 ガス生物学 血管内皮学 酸化ストレス |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2015-12-01 |
| Volume | volume127 |
| Issue | issue3 |
| Start Page | 187 |
| End Page | 195 |
| ISSN | 0030-1558 |
| language | Japanese |
| Copyright Holders | Copyright (c) 2015 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.127.187 |
| NAID | 130005116819 |
| JaLCDOI | 10.18926/AMO/53675 |
|---|---|
| FullText URL | 69_5_291.pdf |
| Author | Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji| |
| Abstract | Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies. |
| Keywords | breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2015-10 |
| Volume | volume69 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 291 |
| End Page | 299 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26490026 |
| Web of Science KeyUT | 000365519600005 |
| Title Alternative | A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy |
|---|---|
| FullText URL | 127_127.pdf |
| Author | Kiura, Katsuyuki| Hotta, Katsuyuki| Sato, Akiko| Ohashi, Kadoaki| Ninomiya, Takashi| Minnami, Daisuke| Tabata, Masahiro| Kubo, Toshio| Kato, Yuka| Hirata, Taizo| |
| Keywords | 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2015-08-03 |
| Volume | volume127 |
| Issue | issue2 |
| Start Page | 127 |
| End Page | 132 |
| ISSN | 0030-1558 |
| Related Url | isVersionOf https://doi.org/10.4044/joma.127.127 |
| language | Japanese |
| Copyright Holders | Copyright (c) 2015 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.127.127 |
| NAID | 130005096256 |
| FullText URL | K0005085 abstract_review.pdf K0005085_fulltext.pdf |
|---|---|
| Author | Kawahara, Michiko| |
| Published Date | 2015-03-25 |
| Content Type | Thesis or Dissertation |
| Grant Number | 甲第5085号 |
| Granted Date | 2015-03-25 |
| Thesis Type | Doctor of Philosophy in Medical Science |
| Grantor | 岡山大学 |
| language | English |
